Safety and pharmacokinetics of chimeric anti-shiga toxin 1 and anti-shiga toxin 2 monoclonal antibodies in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3081-3087

  Bitzan, Martin ^a   Poole, Ruth ^b   Mehran, Mariam ^b,e   Sicard, Eric ^c   Brockus, Catherine ^d   Thuning Roberson, Claire ^b   Rivière, Marc ^b,f  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b Thallion Pharmaceuticals Inc   (Canada)

^c Algorithme Pharma Inc   (Canada)

^d MPI RESEARCH   (United States)

^e METHYLGENE INC   (Canada)

^f Axcan Pharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC ANTIBODY SHIGA TOXIN 1; CHIMERIC ANTIBODY SHIGA TOXIN 2; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VEROTOXIN 1; VEROTOXIN 2;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSPHONIA; DYSURIA; FEMALE; FEVER; HEADACHE; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; HYPERACTIVITY; HYPOCALCEMIA; INFLUENZA; INJECTION SITE IRRITATION; LYMPHADENOPATHY; MALE; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NEUTROPHILIA; PARESTHESIA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PYURIA; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SINGLE DRUG DOSE; SKIN IRRITATION; SOMNOLENCE; THROMBOCYTOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; SHIGA TOXIN 1; SHIGA TOXIN 2; YOUNG ADULT;

EID: 67649960166     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01661-08     Document Type: Article

References (27)

1. Bell, B. P., P. M. Griffin, P. Lozano, D. L. Christie, J. M. Kobayashi, and P. I. Tarr. 1997. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 100:E12.
2. Bielaszewska, M., A. W. Friedrich, T. Aldick, R. Schurk-Bulgrin, and H. Karch. 2006. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin. Infect. Dis. 43:1160-1167.
3. Bitzan, M. 2009. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int. 75(Suppl. 112):S62-S66.
4. Blanco, J. E., M. Blanco, M. P. Alonso, A. Mora, G. Dahbi, M. A. Coira, and J. Blanco. 2004. Serotypes, virulence genes, and intimin types of Shiga toxin (verotoxin)-producing Escherichia coli isolates from human patients: prevalence in Lugo, Spain, from 1992 through 1999. J. Clin. Microbiol. 42:311-319.
5. Carter, A. O., A. A. Borczyk, J. A. Carlson, B. Harvey, J. C. Hockin, M. A. Karmali, C. Krishnan, D. A. Korn, and H. Lior. 1987. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N. Engl. J. Med. 317:1496-1500.
6. Dowling, T. C., P. A. Chavaillaz, D. G. Young, A. Melton-Celsa, A. O'Brien, C. Thuning-Roberson, R. Edelman, and C. O. Tacket. 2005. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob. Agents Chemother. 49:1808-1812.
7. Dundas, S., W. T. Todd, A. I. Stewart, P. S. Murdoch, A. K. Chaudhuri, and S. J. Hutchinson. 2001. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin. Infect. Dis. 33:923-931.
8. Edwards, A. C., A. R. Melton-Celsa, K. Arbuthnott, J. R. Stinson, C. K. Schmitt, H. C. Wong, and A. D. O'Brien. 1998. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against Escherichia coli toxins Stx1 and Stx2, p. 388-392. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, DC.
9. Elliott, E. J., R. M. Robins-Browne, E. V. O'Loughlin, V. Bennett-Wood, J. Bourke, P. Henning, G. G. Hogg, J. Knight, H. Powell, and D. Redmond. 2001. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch. Dis. Child. 85:125-131.
10. Friedrich, A. W., M. Bielaszewska, W. L. Zhang, M. Pulz, T. Kuczius, A. Ammon, and H. Karch. 2002. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 185:74-84.
11. Karch, H., M. Bielaszewska, M. Bitzan, and H. Schmidt. 1999. Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections. Diagn. Microbiol. Infect. Dis. 34:229-243.
12. Kawano, K., M. Okada, T. Haga, K. Maeda, and Y. Goto. 2008. Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157. Eur. J. Clin. Microbiol. Infect. Dis. 27:227-232.
13. Klein, E. J., J. R. Stapp, C. R. Clausen, D. R. Boster, J. G. Wells, X. Qin, D. L. Swerdlow, and P. I. Tarr. 2002. Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study. J. Pediatr. 141: 172-177.
14. Leotta, G. A., E. S. Miliwebsky, I. Chinen, E. M. Espinosa, K. Azzopardi, S. M. Tennant, R. M. Robins-Browne, and M. Rivas. 2008. Characterisation of Shiga toxin-producing Escherichia coli O157 strains isolated from humans in Argentina, Australia and New Zealand. BMC Microbiol. 8:46.
15. Manning, S. D., A. S. Motiwala, A. C. Springman, W. Qi, D. W. Lacher, L. M. Ouellette, J. M. Mladonicky, P. Somsel, J. T. Rudrik, S. E. Dietrich, W. Zhang, B. Swaminathan, D. Alland, and T. S. Whittam. 2008. Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks. Proc. Natl. Acad. Sci. USA 105:4868-4873.
16. O'Brien, A. D., V. L. Tesh, A. Donohue-Rolfe, M. P. Jackson, S. Olsnes, K. Sandvig, A. A. Lindberg, and G. T. Keusch. 1992. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 180:65-94.
17. Ochoa, T. J., and T. G. Cleary. 2003. Epidemiology and spectrum of disease of Escherichia coli O157. Curr. Opin. Infect. Dis. 16:259-263.
18. Orth, D., K. Grif, L. B. Zimmerhackl, and R. Würzner. 2008. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. Expert Rev. Anti-Infect. Ther. 6:101-108.
19. Perera, L. P., L. R. Marques, and A. D. O'Brien. 1988. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J. Clin. Microbiol. 26:2127-2131.
20. Rivas, M., E. Miliwebsky, I. Chinen, C. D. Roldan, L. Balbi, B. Garcia, G. Fiorilli, S. Sosa-Estani, J. Kincaid, J. Rangel, and P. M. Griffin. 2006. Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathog. Dis. 3:88-96.
21. Sauter, K. A., A. R. Melton-Celsa, K. Larkin, M. L. Troxell, A. D. O'Brien, and B. E. Magun. 2008. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect. Immun. 76:4469-4478.
22. Siegler, R., and R. Oakes. 2005. Hemolytic uremic syndrome; pathogenesis, treatment, and outcome. Curr. Opin. Pediatr. 17:200-204.
23. Smith, M. J., H. M. Carvalho, A. R. Melton-Celsa, and A. D. O'Brien. 2006. The 13C4 monoclonal antibody that neutralizes Shiga toxin type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect. Immun. 74:6992-6998.
24. Strockbine, N. A., L. R. Marques, R. K. Holmes, and A. D. O'Brien. 1985. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect. Immun. 50:695-700.
25. Tarr, P. I., C. A. Gordon, and W. L. Chandler. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086.
26. Trachtman, H., A. Cnaan, E. Christen, K. Gibbs, S. Zhao, D. W. Acheson, R. Weiss, F. J. Kaskel, A. Spitzer, and G. H. Hirschman. 2003. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 290:1337-1344.
27. Tzipori, S., A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17:926-941.